<p>Heartseed is developing regenerative cell therapies for severe heart failure using high-purity ventricular cardiomyocytes derived from iPS cells organized into cardiomyocyte spheroids to support engraftment while minimizing risks of tumorigenesis and arrhythmia. The company claims it is advancing tw</p>